Elatan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elatan

Elatan: Identity, Classification, and General Purpose

Property Description
Active ingredient Isosorbide Mononitrate (ISMN)
Form Oral Tablets (Standard and Extended-Release)
Pharmacological Class Organic Nitrates / Antianginal Agent
Primary Action Vasodilation (Vessel Relaxation)
Origin Synthetic Chemical Derivative

Defining the Isosorbide Mononitrate Entity

Elatan is a prescription medication containing the single active component Isosorbide Mononitrate (ISMN), a synthetic compound classified chemically as an organic nitrate. A key feature of ISMN is that it is the major biologically active metabolite of related nitrates, meaning it achieves high and consistent bioavailability upon ingestion. This property allows the drug to be reliably delivered via the oral route as tablets, including specialized extended-release formulations designed for sustained therapeutic effect.

Pharmacological Classification and Action

Elatan belongs to the therapeutic category of Antianginal Agents and functions primarily as a Vasodilator. This class of medication is recognized for its ability to reduce cardiac workload by acting as a nitric oxide donor to the vascular smooth muscle, triggering relaxation. This vasodilating effect is key to the drug's purpose, as the class helps decrease cardiac work by lowering peripheral resistance, which is essential for managing chronic heart-related strain.

General Therapeutic Purpose

The overarching purpose of using this organic nitrate is to provide continuous, prophylactic support for the cardiovascular system. Unlike fast-acting nitrates used for immediate relief, the extended-release form of Isosorbide Mononitrate is designed for ongoing management. By reducing the load placed on the heart, the medication helps to improve the critical balance between the heart muscle's oxygen demand and its overall supply, which is the foundational therapeutic benefit provided in chronic cardiovascular care.

Regulatory References

  1. Isosorbide Mononitrate Extended-Release Tablets - FDA Label (via DailyMed)
  2. Isosorbide - StatPearls - NIH/NCBI Bookshelf

What side effects are possible with Elatan?

Possible Side Effects and Safety Information

The safety profile for Elatan (Isosorbide Mononitrate) is characterized by adverse reactions stemming from its vasodilating effects, as documented in official regulatory labeling. These reactions are classified by frequency, with many being transient.


Officially Documented Adverse Reactions

Frequency Classification Examples of Effects (SOC Group)
Very Common (ge 1/10) Headache (Nervous System)
Common (ge 1/100 to <1/10) Dizziness, Hypotension, Tachycardia, Fatigue (Nervous, Vascular, Cardiac)
Uncommon (ge 1/1,000 to <1/100) Nausea, Vomiting, Flushing (GI, Vascular)
Rare (ge 1/10,000 to <1/1,000) Rash, Syncope (Skin, Nervous System)

Regulatory Safety Patterns and Constraints

The most frequent adverse reaction, headache, is explicitly noted in regulatory documents as being very common at the start of treatment or following a dose increase, but typically diminishes or disappears with continued use over one to three weeks. Dizziness and hypotension also commonly occur early in therapy.

Serious adverse reactions documented include cases of severe hypotension that may lead to circulatory collapse (shock), and a paradoxical aggravation of angina pectoris may occur. Furthermore, the medication is contraindicated for use with Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil) and Soluble Guanylate Cyclase (sGC) Stimulators due to the risk of profound and life-threatening low blood pressure. Safety considerations for special populations note that use during pregnancy and lactation is generally not established, and caution is advised for patients with existing low blood pressure or specific heart conditions.

Overdose and Emergency Response

Overdose of Elatan (Isosorbide Mononitrate) is primarily documented in regulatory sources as a result of profound, exaggerated vasodilation. The documented clinical manifestations are dominated by severe hemodynamic instability, leading to signs such as severe hypotension, a persistent pulsating headache, and flushing. Other documented signs include vertigo, confusion, syncope (fainting), and potentially reflex changes in heart rate, such as tachycardia or bradycardia. Gastrointestinal symptoms, including vomiting and diarrhea, have also been reported.

The most serious potential outcomes documented in official labeling are circulatory collapse and methemoglobinemia. Methemoglobinemia is a severe complication of very high nitrate exposure that impairs oxygen delivery throughout the body. Immediate medical attention must be sought if any of these symptoms or complications are recognized, and emergency services or a Poison Control Center should be contacted.

The management procedures described in official documents are symptomatic and supportive. These include addressing hypotension with measures such as passive elevation of the patient's legs and intravenous fluid administration. For documented methemoglobinemia, the specific intervention is the administration of Methylene Blue. There is no specific antidote listed for the vasodilation effects themselves, and the use of certain vasoconstrictors is noted to be potentially harmful in this context.

Therapeutic Uses of Elatan

What Elatan Treats: Main Uses and Benefits

Elatan, which is Isosorbide Mononitrate, is applied across therapeutic domains where long-term symptomatic support is needed for chronic cardiovascular conditions. Its primary role contributes to continuous prophylactic support, particularly in conditions marked by increased physiological stress, to assist with maintaining functional stability. The medication provides a role in supporting symptomatic management.

This medication is applied in addressing situations involving recurrent or episodic manifestations of Angina Pectoris. The therapeutic applications generally include the management of recurrent anginal chest pain and support for chronic heart conditions. It is considered relevant in contexts involving episodic or fluctuating manifestations related to coronary artery disease. The medication may help reduce the frequency and intensity of recurrent chest discomfort, pressure, or tightness—the classic symptoms related to physical discomfort. This continuous supportive relief helps ease the overall symptom burden associated with chronic heart strain and contributes to improved day-to-day comfort.


Quick Fact: Support for Recurrent Chest Pain (This medication is generally used to help with symptomatic support during phases where recurrent painful anginal episodes may be disruptive.)

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

The official labeling defines specific population groups who can and cannot use Elatan (Isosorbide Mononitrate). Use of this medication is contraindicated in patients with a known hypersensitivity to nitrates or nitrites, and in those concurrently using Phosphodiesterase Type 5 (PDE-5) inhibitors (such as sildenafil) or Soluble Guanylate Cyclase (sGC) stimulators (such as riociguat). It is also prohibited in patients experiencing acute circulatory failure, cardiogenic shock, marked hypotension (systolic blood pressure below 90 mmHg), or severe anaemia.

Regarding age, the medication is approved for use in the adult population, including older adults. However, its safety and efficacy have not been established in the pediatric population (children and adolescents). Patients with chronic renal impairment or liver cirrhosis are generally permitted to use the medicine, as regulatory studies indicate that no dosage adjustment is necessary.

Use requires caution in patients who are volume-depleted or who have conditions like hypertrophic cardiomyopathy (HCM). Furthermore, the medicine is not recommended in the acute phases of myocardial infarction or congestive heart failure. During pregnancy and lactation, use is restricted and requires careful consideration, as it is not known if the drug is excreted in human milk.

What should I know about interactions with other medicines?

Elatan Interactions with other medicines and products

The official regulatory documentation for Elatan (Isosorbide Mononitrate) defines the interaction profile primarily by severe pharmacodynamic consequences, which lead to explicit restrictions on co-administration with certain substance categories.

Interaction Classification Documented Substances and Patterns
Contraindicated Combinations Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil) are strictly prohibited due to the risk of severe, life-threatening hypotension and syncope. The Soluble Guanylate Cyclase (sGC) Stimulator Riociguat is also contraindicated due to the risk of profound hypotension.
Pharmacodynamic Interactions The co-administration of other vasodilators (such as calcium channel blockers) or alcohol (ethanol) may lead to an additive hypotensive effect, increasing the risk of symptomatic orthostatic low blood pressure.

Official Interaction Statements:

  • Co-administration with PDE-5 inhibitors and Riociguat is a documented prohibition based on the high risk of severe hypotension.
  • Additive hypotensive effects are explicitly noted in regulatory documents when combined with other vasodilating medications or with alcohol consumption.
  • The official labeling specifies that food does not significantly affect the absorption or overall bioavailability of Elatan tablets.

The regulatory profile is structured around these critical pharmacodynamic prohibitions and cautions, with no mandatory warnings or constraints related to major CYP enzyme metabolism, drug transporters, or timing separation rules for non-contraindicated products.

Mechanism of Action

Molecular Action: Nitric Oxide Activation of the cGMP Pathway

Elatan (Isosorbide Mononitrate) engages a core mechanism by serving as a Nitric Oxide (NO) donor, a gaseous messenger that diffuses into vascular smooth muscle cells. The NO binds to and activates the intracellular enzyme Soluble Guanylyl Cyclase (sGC), which increases the production of the second messenger cyclic Guanosine Monophosphate (cGMP). This cascade initiates the chain of events leading to the relaxation of the muscle cell.


Cellular Outcome: Vasodilation and Reduced Preload

The elevated cGMP levels modulate the cell's phosphorylation balance, leading directly to the physical relaxation and widening of blood vessels (vasodilation). This effect is most pronounced in the veins, which are the capacitance vessels of the circulation. By expanding the venous capacity, the drug reduces the volume of blood returning to the heart, thereby lowering the Preload (the volume load) exerted on the heart muscle.


Systemic Constraint: The Mechanism of Nitrate Tolerance

The effectiveness of this mechanism is subject to a predictable constraint known as Nitrate Tolerance (tachyphylaxis), where the vasodilating response diminishes after continuous exposure. This loss of effect is a purely pharmacodynamic limitation, linked to the hypothesized depletion of co-factors required for the initial bioactivation of the drug into NO, and is further linked to the need for a drug-free period to allow for pathway regeneration.

Dosage and Administration Information

How to Use Elatan

The administration of Elatan (Isosorbide Mononitrate) is governed by the need to ensure a daily nitrate-free interval, which is essential for maintaining the medication's effectiveness over long-term use.


Official Dosing and Administration

Parameter Official Instruction
Route of Administration Oral route (swallowed).
Immediate-Release (IR) Dosing Typically 20 mg twice daily. The starting dose may be lower for smaller individuals, at 5 mg twice daily, before increasing.
Extended-Release (ER) Dosing Starting dose is 30 mg or 60 mg once daily; maintenance ranges up to 120 mg once daily.
Timing and Frequency IR tablets must be taken 7 hours apart to create the necessary 17-hour drug-free period. ER tablets are taken once daily in the morning.
Administration Method Extended-release tablets must be swallowed whole with fluid; they should not be crushed, chewed, or split, as this compromises the sustained-release mechanism. The medication can be taken with or without food.

Population-Specific Guidelines

Treatment for older adults should be initiated at the low end of the dosing range. The safety and effectiveness of this medication have not been established in the pediatric patient population (individuals under 18 years of age).

These administration guidelines define the dosage, timing, and method of ingestion for the medication.

Recent Clinical Evidence

Research evidence / Overview of studies for Elatan


Evidence for Preventing Chronic Angina Pectoris

Research on Elatan (Isosorbide Mononitrate) primarily focuses on its evaluation for the prophylactic management of chronic stable chest pain. The core evidence for this use comes from Randomized Controlled Trials (RCTs), where studies examined how symptoms change over defined time intervals. The primary focus of these trials was measuring functional capacity (exercise tolerance) and symptom frequency (number of chest pain episodes).

Findings describe patterns observed in the studies over the short to intermediate term, regarding measured functional capacity and symptom frequency. What remains uncertain is the durability of the effect. Studies consistently highlight that to manage the potential for tolerance observed in research, patients in the trials required a planned period each day where they did not receive the medication—known as a nitrate-free interval. Research provides insight into short-term changes, but there is limited information for long-term outcomes.


Evidence in the Context of Chronic Heart Failure

Elatan was studied for chronic heart failure, a condition associated with acute or disruptive episodes. Studies explored its use both as a single agent and as part of a combination regimen with other vasodilating medications. Research has explored outcomes reflecting daily functioning or activity level.

Findings for the heart failure population were mixed; some research describes patterns related to limited changes in activity levels compared to placebo. Conversely, evidence for the nitrate class in specific combination therapies for heart failure with reduced ejection fraction contributes to the broader evidence landscape. Data are still emerging, and research does not determine whether an individual will respond similarly across all heart failure types.


Gaps in the Evidence and Areas of Uncertainty

A key limitation noted consistently across various studies is the need for a nitrate-free interval to address the body's tendency to develop tolerance. Long-term effects are not fully established; there are limited data on whether Elatan affects survival rates or the overall long-term progression of coronary artery disease. Findings were mixed in some recent heart failure trials, indicating where more research is needed, especially concerning patient-reported outcomes describing perceived discomfort.

Key Studies & References

  1. Isosorbide Mononitrate Extended-Release Tablets, USP Prescribing Information
  2. Nitrate's Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT-HFpEF) Trial Results
  3. Nitrates in Congestive Heart Failure (NICE) Study - American College of Cardiology
  4. Isosorbide Mononitrate Final Print Label: Clinical Pharmacology and Pharmacokinetics

Frequently Asked Questions (FAQ)

Common questions about Elatan (FAQ)


Q: Does Elatan start working right away?

A: The extended-release formulation of Elatan is designed for ongoing prevention (prophylaxis) and is not intended for the immediate relief of sudden chest pain. Official information indicates the onset of its anti-anginal effect has an onset that is generally described as approximately 30 minutes.


Q: How long does it take for Elatan's effects to wear off?

A: Regulatory documents indicate that the rate at which the drug leaves the body is measured by its half-life, which is approximately 5 hours for the active ingredient, Isosorbide Mononitrate. The overall sustained effect of the extended-release forms is planned to last about 8 to 12 hours before a required daily break.


Q: What happens if I forget to take Elatan?

A: Official patient information advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the instruction is to skip the missed dose to maintain the required drug-free interval. Official guidance states that a double dose should not be taken.


Q: Can I take Elatan with my vitamins or supplements?

A: Official patient information indicates that a healthcare provider should be informed about all products being used. This includes prescription medicines, over-the-counter (OTC) medicines, vitamins and minerals, herbal remedies, and any other supplements.


Q: Is it normal to feel tired after starting Elatan?

A: Yes, regulatory reports list tiredness (fatigue) and drowsiness as commonly reported effects when taking isosorbide mononitrate. If these feelings are persistent or concerning, the official information advises consulting a healthcare provider.


Q: Are there any long-term side effects associated with Elatan?

A: Official warnings mention that studies in workers with chronic, high exposure to nitrates showed evidence of physical dependence and withdrawal symptoms upon temporary cessation. The significance of this finding for individuals taking standard clinical doses is not established.


Q: What is the risk of dependence or addiction with Elatan?

A: Regulatory warnings mention that studies involving high, long-term exposure to nitrates in industrial settings demonstrated a true risk of physical dependence. While this is noted in official documentation, the relevance to people taking typical clinical doses is not established.


Q: Can Elatan affect my mood or mental state?

A: Official side effect reports from studies list emotional lability (mood swings) and sleep disturbances as commonly reported effects. Other reported effects in the same category include anxiety, depression, insomnia, nervousness, and nightmares.


Q: Can Elatan be taken with over-the-counter pain relievers?

A: Official guidance notes that acetaminophen (Paracetamol) is generally considered safe to take with Elatan, often to help with headaches. However, for other pain relievers, such as NSAIDs (like ibuprofen or naproxen), official information advises consulting a healthcare provider due to potential interactions.


Q: Are there warnings about driving or operating machinery while on Elatan?

A: Yes. Official patient information notes that the medication can potentially affect alertness or coordination because it may cause dizziness, blurred vision, or light-headedness. Patients are advised not to drive or operate complex machinery until they know how the drug affects them.


Q: What does the official drug label say about Elatan?

A: The official drug label (Prescribing Information or SmPC) is a regulatory document that contains detailed, factual information about the drug's approved use, safety, interactions, and dosing, as mandated by government authorities. These documents are typically made publicly available via official government websites like DailyMed (NIH) or the EMA.


Q: Has Elatan been studied in pregnant people?

A: There is a lack of adequate and well-controlled studies conducted specifically in pregnant women. Animal reproduction studies have been performed, which have occasionally shown adverse effects at very high doses, but these findings do not conclusively determine the risk to the human unborn child.


Q: What is the difference between the generic and brand name Elatan?

A: Elatan is a brand name for the drug whose generic name is Isosorbide Mononitrate. Regulatory documents confirm that the drug is available under both the brand and generic names. Both versions contain the same active medicinal component, but may have different inactive ingredients.


Q: What are the main ingredients in the Elatan tablet/capsule?

A: The single active ingredient is Isosorbide Mononitrate. The inactive ingredients used for binding, color, and structure (e.g., lactose monohydrate, magnesium stearate, silicon dioxide, dyes) can vary based on the manufacturer and whether the tablet is immediate- or extended-release.


Q: Where can I find the official patient information leaflet for Elatan?

A: The official Patient Information Leaflet (PIL) or Consumer Medicine Information (CMI) is provided inside the medication package. It is also made publicly available online on government and authoritative medical resource websites, such as the electronic Medicines Compendium (eMC) in the UK or DailyMed (NIH) in the US.


Q: Is Elatan considered a controlled substance?

A: No. Official regulatory labels and drug databases specify that the active ingredient, Isosorbide Mononitrate, is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA).


Q: Does Elatan interact with blood thinners?

A: Official drug interaction checkers indicate that isosorbide mononitrate has moderate interactions with certain blood-thinning or antiplatelet agents (e.g., Aspirin, Clopidogrel). Therefore, cautious use is indicated with co-administration.


Q: Can I take cold or flu medicine while using Elatan?

A: Official patient guidance recommends consulting a healthcare provider about the use of cold or flu products. This is because some common cold and flu medicines contain ingredients that could either worsen specific heart conditions or interact with Elatan.


Q: How quickly does Elatan leave the body?

A: The rate at which the drug is eliminated is represented by its half-life, which is approximately 5 hours for the active component, Isosorbide Mononitrate. The medication is designed to be fully eliminated during the planned drug-free interval each day.


Q: Does Elatan cause weight changes?

A: Official reports on adverse reactions list both decreased weight (weight loss) and increased appetite as potential side effects. These effects are reported from clinical experience but occur with an unknown frequency.


Q: Why do some people need to adjust their Elatan use over time?

A: The specific use schedule and potential adjustments are necessary to manage the risk of nitrate tolerance, which is a condition where the drug’s effectiveness diminishes with continuous use. Maintaining a daily drug-free interval is required to restore the drug’s biological activity.


Q: Are there any lab tests required before or during Elatan use?

A: Official documents note that organic nitrates can interfere with a specific laboratory test for serum cholesterol determination (the Zlatkis-Zak color reaction). This interference may lead to falsely low cholesterol readings.


Q: What information is available about discontinuing Elatan?

A: Regulatory warnings state that abruptly stopping nitrates after long-term exposure may lead to withdrawal symptoms, such as the return of chest pain or, in rare cases, a heart attack. Official guidance states that the medication should not be stopped suddenly.


Q: Is Elatan available as a generic version?

A: Yes. Regulatory documents confirm that the drug is available under its generic name, Isosorbide Mononitrate. This means both brand name products, like Elatan, and generic versions containing the same active ingredient are available.


Q: What if I have an allergic reaction to Elatan?

A: Signs of a serious allergic reaction, such as a severe rash, swelling of the face or throat, or difficulty breathing, are listed as events that require immediate medical attention. Official safety information lists these as potential, though rare, adverse events.


Q: Are there any known interactions between Elatan and herbal remedies?

A: Official patient information advises informing a healthcare provider about all products being used. This includes prescription and over-the-counter medicines, vitamins/minerals, herbal products, and other supplements.


Q: What should I look out for after starting Elatan?

A: Patients are advised to watch for common effects like headache, dizziness, and light-headedness, especially when standing up, as these typically occur early in therapy and often lessen over time. Official guidance advises against driving or operating machinery until the effects of the drug are known.

How should Elatan be stored and disposed of?

Elatan (Isosorbide Mononitrate) must be stored at a controlled room temperature, specifically between 59 F and 86 F (15 C and 30 C). The medication must be kept in its original container with the cap tightly closed and protected from excessive heat and moisture; storage in the bathroom is prohibited.

Storage Restriction Requirement
Child Safety Keep out of the sight and reach of children.
Environmental Protection Do not flush down the toilet or throw into wastewater.

Disposal of unused or expired Elatan should follow the official procedure: utilize a medicine take-back program if one is available. If not, tablets must be mixed with an undesirable substance, sealed in a bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elatan found in:

A-Z Index: